Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022

Findings to showcase the promise of company's 'Macrophage Conditioning' approach in reversing immunosuppression within acidic tumor microenvironment and driving anti-tumor activity

OXFORD, UK, Nov. 3, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that new preclinical data highlighting the therapeutic potential of the company's novel GPR65 inhibition platform will be the focus of a poster presentation at the upcoming 37^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022). Presented results will showcase the company's unique approach to "macrophage conditioning" with novel GPR65 inhibitors as a means to reversing the immunosuppression that results from an acidic tumor microenvironment, and, in turn, driving anti-tumor activity. SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.

Details of the company's presentation at SITC 2022 are as follows:

• Title: Inhibition of Acid Sensing by GPR65 Normalizes Gene Expression in Macrophages, Increases Immune Cell Infiltration in Tumors, and Restrains Subcutaneous MC38 Growth in Mice
• Presenting Author: Alastair Corbin, DPhil, senior scientist at Pathios
• Date/Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. Eastern Time
• Location: Poster Hall C

Additional information on the 37^th Annual Meeting of SITC is available through the conference website at: https://www.sitcancer.org/2022/home

The acidic tumor microenvironment, inherent to many cancers, causes a profound immunosuppression of infiltrating immune cells. This environment disarms the anti-cancer immune response and negates the effectiveness of current immunotherapies. This is particularly evident in tumor associated macrophages (TAM), where acidity is sensed by the cell-surface receptor GPR65, leading to the widespread suppression of a host of pro-inflammatory mediators and anti-tumorigenic genes, as well as the upregulation of several tissue repair genes and angiogenic factors.

Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. The company is focused on developing small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to target immunosuppressive macrophages in advanced cancers. To date, Pathios has secured a total of US$33M in Series A funding from the leading venture capital firms, Canaan Partners, and Brandon Capital. Pathios is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit www.pathios.com.

Contacts
Pathios Therapeutics
Stuart Hughes, Chief Executive Officer, +44 1865 292 039
[email protected]

Tim Brons
Vida Strategic Partners (media)
646-319-8981
[email protected]

SOURCE Pathios Therapeutics